Topics

Novartis axed Avexis execs ahead of Zolgensma scandal

07:08 EDT 15 Aug 2019 | pharmaphorum

The plot thickens at Novartis, which is becoming embroiled in a scandal over falsification of data related to its rare disease gene therapy Zolgensma. It emerged yesterday that it replaced the two top executives at its Avexis unit, which conducted...

Original Article: Novartis axed Avexis execs ahead of Zolgensma scandal

NEXT ARTICLE

More From BioPortfolio on "Novartis axed Avexis execs ahead of Zolgensma scandal"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...